tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michelle Gilson, 55 are a BUY (94.83%), 3 are a HOLD (5.17%).
Analyst Michelle Gilson, carries an average stock price target met ratio of 47.27% that have a potential upside of 32.78% achieved within 213 days. Previously, Michelle Gilson worked at CANACCORD.
Michelle Gilson’s has documented 107 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VIR, Vir Biotechnology at 07-Jan-2025.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $60 was fulfilled within 8 days with a profit of $27.55 (84.9%) receiving and performance score of 106.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$254
$52 (25.74%)
$200
14 days ago
(12-Oct-2025)
19/20 (95%)
$45.57 (21.86%)
347
Buy
$264
$62 (30.69%)
$260
18 days ago
(08-Oct-2025)
23/27 (85.19%)
$49.23 (22.92%)
150
Buy
$230
$28 (13.86%)
$216
1 months 25 days ago
(01-Sep-2025)
13/15 (86.67%)
$30.84 (15.49%)
259
Buy
$243
$41 (20.30%)
$207
3 months 16 days ago
(10-Jul-2025)
11/12 (91.67%)
$68.04 (38.89%)
743
Buy
$224
$22 (10.89%)
$180
4 months 14 days ago
(12-Jun-2025)
9/11 (81.82%)
$53.2 (31.15%)
1013
What Year was the first public recommendation made by Michelle Gilson?
